Narod S A, Neuhausen S, Vichodez G, Armel S, Lynch H T, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes W D, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P, Danquah Jessica, Domchek Susan, Tung Nadine, Ainsworth Peter, Horsman Douglas, Kim-Sing Charmaine, Maugard Christine, Eisen Andrea, Daly Mary, McKinnon Wendy, Wood Marie, Isaacs Claudine, Gilchrist Dawna, Karlan Beth, Nedelcu Raluca, Meschino Wendy, Garber Judy, Pasini Barbara, Manoukian Siranoush, Bellati Christina
Women's College Research Institute, 790 Bay Street, 7th Floor, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
Br J Cancer. 2008 Jul 22;99(2):371-4. doi: 10.1038/sj.bjc.6604453. Epub 2008 Jun 24.
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
已发现携带BRCA2突变的男性患前列腺癌的风险增加。最近有报告称，患有前列腺癌的BRCA2携带者的生存率低于非携带者前列腺癌患者。在本研究中，我们比较了携带BRCA2突变的前列腺癌男性与携带BRCA1突变的前列腺癌男性的生存率。我们从182名来自BRCA2突变家族的前列腺癌男性和119名来自BRCA1突变家族的前列腺癌男性中获取了诊断年龄、死亡年龄或当前年龄。携带BRCA2突变的男性从诊断开始的中位生存期为4.0年，而携带BRCA1突变的男性为8.0年，差异非常显著（P<0.01）。开发针对性化疗方法来治疗携带BRCA2突变的男性前列腺癌可能很重要。
